Vera Therapeutics CRO granted RSUs and options

Vera Therapeutics Chief Regulatory Officer receives new equity awards.

Rhea-AI Filing Summary

Vera Therapeutics Chief Regulatory Officer receives new equity awards. William D. Turner was granted 25,000 restricted stock units (RSUs) of Class A Common Stock and a stock option covering 50,000 shares. The option has a $42.74 exercise price and was granted for no cash consideration.

One-fourth of the RSUs vest on each of February 20, 2027, 2028, 2029 and 2030, if he remains in service. The option vests in 48 equal monthly installments, starting March 4, 2026, also subject to continued service. After these grants, he directly holds 47,500 Class A shares and 50,000 options.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 2 txns

Insider Turner William D.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00
Grant/Award	Class A Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct); Class A Common Stock — 47,500 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
2. F2. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did Vera Therapeutics (VERA) grant to its CRO?

Vera Therapeutics granted Chief Regulatory Officer William D. Turner 25,000 restricted stock units and a stock option for 50,000 Class A Common shares. Both grants were awarded for no cash consideration as part of his equity compensation.

How do William D. Turner’s new RSUs at Vera Therapeutics (VERA) vest?

The 25,000 RSUs vest in four equal annual installments. One-fourth vests on each of February 20, 2027, 2028, 2029 and 2030, provided Turner maintains continuous service with Vera Therapeutics through each scheduled vesting date.

What are the key terms of William D. Turner’s new stock option at Vera Therapeutics (VERA)?

The stock option covers 50,000 Class A Common shares at a $42.74 exercise price. It was granted on February 4, 2026 and expires on February 3, 2036, giving long-term potential to purchase company stock.

What is the vesting schedule for the new Vera Therapeutics (VERA) stock option?

The option vests over 48 months. One-forty-eighth of the 50,000 shares vests and becomes exercisable on March 4, 2026, with additional one-forty-eighth portions vesting monthly thereafter, conditioned on Turner’s continued service.

How many Vera Therapeutics (VERA) shares does William D. Turner own after these grants?

Following the reported transactions, William D. Turner directly beneficially owns 47,500 shares of Vera Therapeutics Class A Common Stock and holds a stock option covering an additional 50,000 shares, subject to its vesting and exercise conditions.

What role does William D. Turner hold at Vera Therapeutics (VERA)?

William D. Turner serves as Chief Regulatory Officer of Vera Therapeutics. The reported equity grants of RSUs and stock options represent part of his compensation in that executive officer role with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turner William D.

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/04/2026		A		25,000(1)	A	$0	47,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$42.74	02/04/2026		A		50,000		(2)	02/03/2036	Class A Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.

2. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

	/s/ Joseph R. Young, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.